Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study
Kenneth F Hofland, Steinbjørn Hansen, Morten Sorensen, Silke Engelholm, Henrik P Schultz, Aida Muhic, Kirsten Grunnet, Anders Ask, Junia C Costa, Charlotte Kristiansen, Carsten Thomsen, Hans Skovgaard Poulsen, Ulrik Lassen
Dyk ned i forskningsemnerne om 'Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study'. Sammen danner de et unikt fingeraftryk.